Skip to main content
OpenTrials

Clinical trial condition

Smoldering Multiple Myeloma

Explore clinical trials studying Smoldering Multiple Myeloma. Study availability and eligibility vary by location and protocol.

77 public trials 28 recruiting studies
Refine in advanced search Browse all conditions

Smoldering Multiple Myeloma trial results

Completed

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

NCT01441973

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Sharp Clinical Oncology Research San Diego, California, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Va Connecticut Healthcare System West Haven, Connecticut, United States
  • Winship Cancer Institute. Atlanta, Georgia, United States
View Trial Details
Completed

Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

NCT01718899

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Winship Cancer Institute, Emory University Atlanta, Georgia, United States
  • Illinois Cancer Specialists Niles, Illinois, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

NCT00919139

Conditions
Amyloidosis, Blood Protein Disorders, Cardiovascular Diseases, +25 more
Locations
  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Alta Bates Summit Comprehensive Cancer Center Berkeley, California, United States
  • Peninsula Medical Center Burlingame, California, United States
  • University of California Davis Cancer Center Sacramento, California, United States
View all 207 locations
View Trial Details
Completed

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

NCT00480363

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations
  • Hospital germans Trias i Pujol Badalona, Spain
  • Hospital Clínic i Provincial de Barcelona Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau Barcelona, Spain
  • Hospital del SAS de Jerez de la Frontera Jerez de la Frontera, Spain
View all 13 locations
View Trial Details
Active, Not Recruiting

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

NCT01169337

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Anchorage Oncology Centre Anchorage, Alaska, United States
  • Katmai Oncology Group Anchorage, Alaska, United States
View all 606 locations
View Trial Details

Related conditions